Brean Capital Reiterates Buy On TG Therapeutics Following ASH Presentation
In a research report published Wednesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a $22 price target, as the company presented updated results from its Phase 1/2 trial of TG-1101 plus TGR-1202 for B-cell malignancies.
Aschoff noted, “We continue to believe that the mounting positive and differentiating data from TG, in addition to the ability of a combination therapy owner to price competitively against competing drugs each coming from several companies, will ultimately result in the company’s acquisition.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jonathan Aschoff has a total average return of 15.4% and a 69.7% success rate. Aschoff has a 16.6% average return when recommending TGTX, and is ranked #75 out of 3401 analysts.